1. Home >
  2. M&A >
  3. Growth Capital >
  4. Canada >
  5. Ontario >
  6. ArchiMed Invests In Prollenium

Investment Summary

ArchiMed Invests In Prollenium

On January 1, 2021, private equity firm ArchiMed invested in life science company Prollenium

Investment Highlights
  • This is ArchiMed’s 4th transaction in the Life Science sector.
  • This is ArchiMed’s 1st transaction in Canada.
  • This is ArchiMed’s 1st transaction in Ontario.

Investment Summary
Date 2021-01-01
Target Prollenium
Sector Life Science
Investor(s) ArchiMed
Deal Type Growth Capital

Target

Prollenium

Richmond Hill, Ontario, Canada
Prollenium is a developer, manufacturer, and distributor of medical aesthetics products. The company’s product expertise and technical knowledge covers the field of facial aesthetics products, ingredients optimization and technical quality testing. Prollenium’s flagship product Revanesse is a line of cross-linked hyaluronic acid dermal fillers. Prollenium was founded in 2002 and is based in Richmond Hill, Ontario.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

ArchiMed

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.

DEAL STATS #
Overall 20 of 38
Sector: Life Science M&A 4 of 14
Type: Growth Capital M&A Deals 4 of 7
State: Ontario M&A 1 of 1
Country: Canada M&A 1 of 2
Year: 2021 M&A 1 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-01 NAMSA

Northwood, Ohio, United States

NAMSA is a medical research organization providing expert regulatory, laboratory, clinical, and compliance services to medical device and healthcare product manufacturers. NAMSA was established in 1967 and is based in Northwood, Ohio.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-12 Zyto

Dusseldorf, Germany

Zyto is a fully integrated developer, manufacturer and distributor of technologically advanced cancer diagnostics tests and equipment for hospitals, clinics and private medical practices.

Buy -
Mergr

Solution for

Product

Company

Legal